Phibro Animal Health is shutting down its Chicago Heights, Ill., manufacturing facility as part of a strategic consolidation following its MFA acquisition in 2024. Production is expected to cease in summer 2027, affecting about 100 employees. The company says it conducted a comprehensive review of its manufacturing network to align its production footprint with current business needs. Manufacturing will transfer to other Phibro-owned facilities and select third-party contract manufacturers. CEO Dani Bendheim said the decision reflects a long-term effort to improve efficiency and strengthen competitiveness, not the performance of Chicago Heights employees.
This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.
Comments